YMAB — Y-mAbs Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $644.03m
- $566.23m
- $84.82m
- 54
- 17
- 73
- 46
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 207 | 115 | 182 | 106 | 78.6 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | — | 7.71 | 12.5 | 22.5 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 212 | 122 | 202 | 130 | 111 |
Net Property, Plant And Equipment | 4.04 | 6.39 | 5.69 | 2.34 | 1.64 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 216 | 132 | 213 | 141 | 128 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 13.6 | 19.5 | 27.9 | 28.3 | 20.1 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 17.5 | 26.2 | 32.7 | 32.2 | 26.9 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 199 | 106 | 180 | 109 | 101 |
Total Liabilities & Shareholders' Equity | 216 | 132 | 213 | 141 | 128 |
Total Common Shares Outstanding |